AVXL Stock Up 19% after 6-Day Win Streak
Anavex Life Sciences (AVXL) stock hit day 6 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 16% return. The company has gained about $129 Mil in value over the last 6 days, with its current market capitalization at about $813 Mil. The stock remains 11.0% below its value at the end of 2024. This compares with year-to-date returns of 3.6% for the S&P 500.
Comparing AVXL Stock Returns With The S&P 500
The following table summarizes the return for AVXL stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | AVXL | S&P 500 |
|---|---|---|
| 1D | 2.8% | 1.1% |
| 6D (Current Streak) | 19.1% | 1.9% |
| 1M (21D) | 24.6% | 4.3% |
| 3M (63D) | -0.5% | 5.6% |
| YTD 2025 | -11.0% | 3.6% |
| 2024 | 15.4% | 23.3% |
| 2023 | 0.5% | 24.2% |
| 2022 | -46.6% | -19.4% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 168 S&P constituents with 3 days or more of consecutive gains and 8 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 72 | 3 |
| 4D | 86 | 2 |
| 5D | 4 | 3 |
| 6D | 6 | 0 |
| 7D or more | 0 | 0 |
| Total >=3 D | 168 | 8 |
- Rocket Lab Stock’s Next Leg Rides On A Vehicle That Has Not Flown Yet
- What The Headline Growth Rate Hides About JNJ Stock
- What Quadrupled Intel Stock Was Not Foundry Customers
- Netflix Stock Has Fallen On Slowing Sales While Margin And Buybacks Compound Earnings
- A 9-Day Winning Streak Has Kymera Therapeutics Stock Up 17%
- A 7-Day Winning Streak Has Boston Scientific Stock Up 8.6%
Key Financials for Anavex Life Sciences (AVXL)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | – | – |
| Operating Income | $-55.7 Mil | $-52.8 Mil |
| Net Income | $-47.5 Mil | $-43.0 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | – | – |
| Operating Income | $-13.6 Mil | $-12.4 Mil |
| Net Income | $-12.1 Mil | $-11.2 Mil |
While AVXL stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.